GLP1R and metabolic dysfunction-associated steatohepatitis: Semaglutide, a GLP1R agonist, achieved the primary endpoint of NASH resolution without fibrosis worsening in a phase II trial (NCT02970942) and is now in phase III trials (NCT04822181) [149].